April 17, 2026

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Conexiant

April 16, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Conexiant

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

March 26, 2026

The Hidden Differences Between Oral Contraceptives

National adverse-event and prescribing data suggest oral contraceptive formulations differ in reported acne, migraine, anxiety, and depression 

Conexiant

March 23, 2026

Influencer Drug Promotion Raises Concerns

Study highlights regulatory gaps and persuasive risks in social media marketing

Conexiant

May 08, 2024

ObGyn Harassment Prevalence Exposed in Revealing Review

Discover key insights from a systematic review on harassment among ObGyn health care professionals.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

August 09, 2024

Updated Guidance on Contraceptive Use

The CDC has released updated contraceptive guidance for health care providers, emphasizing patient autonomy and evidence-based recommendations to support high-quality, equitable contraceptive care.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant